You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FES PET/CT

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Uterine Cancer Trial in Philadelphia (18F-Fluoroestradiol)

Not yet recruiting
  • Uterine Cancer
  • Philadelphia, Pennsylvania
    Abramson Cancer Center at University of Pennsylvania
Jun 21, 2023

Carcinoma, Lobular Trial ([18F]fluoroestradiol (FES))

Not yet recruiting
  • Carcinoma, Lobular
  • [18F]fluoroestradiol (FES)
  • (no location specified)
Jul 18, 2023

Breast Cancer Trial in Beijing (18F-FES PET/CT scan)

Recruiting
  • Breast Cancer
  • 18F-FES PET/CT scan
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 4, 2022

Breast Cancer, Brain Metastases Trial in New York (Brain Imaging with 18F-FES)

Not yet recruiting
  • Breast Cancer
  • Brain Metastases
  • Brain Imaging with 18F-FES
  • New York, New York
    New York-Presbyterian/Weill Cornell Medical Center
Oct 2, 2023

Assessed by 18F-FES PET/CT in MBC With ER-positive Primary Tumor

Recruiting
  • Breast Cancer
    • Shanghai, Shanghai, China
      Biyun Wang, MD
    Apr 5, 2023

    Estrogen Receptor Positive Breast Cancer, Breast Tumor, Metastatic Breast Cancer Trial in Philadelphia ([18F]FES)

    Active, not recruiting
    • Estrogen Receptor Positive Breast Cancer
    • +2 more
    • Philadelphia, Pennsylvania
      University of Pennsylvania Hospital
    Jul 5, 2022

    Breast Cancer Trial in Irvine (18F-fluoroestradiol PET/CT)

    Recruiting
    • Breast Cancer
    • 18F-fluoroestradiol PET/CT
    • Irvine, California
      Hoag Memorial Hospital Presbyterian
    Jan 5, 2022

    Invasive Lobular Breast Carcinoma Trial in Salt Lake City ([18F]Fluoroestradiol (FES) PET/CT)

    Recruiting
    • Invasive Lobular Breast Carcinoma
    • [18F]Fluoroestradiol (FES) PET/CT
    • Salt Lake City, Utah
      Huntsman Cancer Institute
    Jun 14, 2022

    Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy

    Recruiting
    • Advanced Breast Cancer
    • The combination of Dalpiciclib with physician-selected endocrine therapy
    • Chemotherapy selected by the physician
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    May 22, 2023

    Estrogen Receptor Positive Breast Cancer Trial in Salt Lake City ([18F]Fluoroestradiol (FES) PET/CT)

    Recruiting
    • Estrogen Receptor Positive Breast Cancer
    • [18F]Fluoroestradiol (FES) PET/CT
    • Salt Lake City, Utah
      Huntsman Cancer Institute at University of Utah
    Apr 21, 2022

    18F-FES-PET/CT Parameters on Palbociclib Combined With ET

    Active, not recruiting
    • Metastatic Breast Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Sep 13, 2021

    Breast Cancer Trial in Amsterdam (18F-Fluorestradiol PET/CT scan)

    Active, not recruiting
    • Breast Cancer
    • 18F-Fluorestradiol PET/CT scan
    • Amsterdam, Noord- Holland, Netherlands
      VU University Medical Center
    Oct 7, 2021

    Breast Cancer Trial in Canada (Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline, Diagnostic Imaging: 18F-FES PET/CT -

    Terminated
    • Breast Cancer
    • Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline
    • +2 more
    • Kelowna, British Columbia, Canada
    • +3 more
    Nov 15, 2021

    HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive Trial in United States (procedure, drug,

    Active, not recruiting
    • HER2/Neu Negative
    • +3 more
    • Computed Tomography
    • +3 more
    • Birmingham, Alabama
    • +24 more
    Jan 27, 2023

    Metastatic Breast Cancer Trial in Dijon (18F Fluoroestradiol Radiopharmaceutical with PET/CT)

    Recruiting
    • Metastatic Breast Cancer
    • 18F Fluoroestradiol Radiopharmaceutical with PET/CT
    • Dijon, France
      CGFL
    Aug 2, 2022

    [18F]FES PET/CT in PAH

    Terminated
    • Pulmonary Arterial Hypertension
    • [18F] FES
    • Philadelphia, Pennsylvania
      University of Pennsylvania Hospital
    May 13, 2021

    Metastatic Breast Cancer Trial in Angers, Brest, Saint-Herblain (FES PET/CT)

    Recruiting
    • Metastatic Breast Cancer
    • FES PET/CT
    • Angers, France
    • +2 more
    Aug 24, 2021

    FES F18 PET/CT in Metastatic Breast Cancer Patients

    Recruiting
    • Metastatic Breast Cancer
    • 18F Fluoroestradiol Radiopharmaceutical with PET/CT
    • Long Beach, California
    • +5 more
    Jan 19, 2023

    Estrogen Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7 Trial in Seattle (procedure, drug,

    Terminated
    Has Results
    • Estrogen Receptor Positive
    • +2 more
    • Computed Tomography
    • +4 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jun 28, 2021

    Breast Cancer Female, Lobular Breast Carcinoma, PET/MRI Trial (drug, procedure, genetic)

    Not yet recruiting
    • Breast Cancer Female
    • +4 more
    • (no location specified)
    Aug 8, 2023

    Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

    Recruiting
    • Breast Cancer
    • +2 more
      • Wuhan, Hubei, China
        TongjiHospital
      Sep 12, 2022

      Breast Cancer Trial in Dallas (drug, procedure, other)

      Withdrawn
      • Breast Cancer
      • F-18 Fluoroestradiol
      • +3 more
      • Dallas, Texas
        Clements University Hospital
      May 8, 2020

      Breast Cancer Trial in Amsterdam (FES)

      Recruiting
      • Breast Cancer
      • Amsterdam, North-Holland, Netherlands
        Amsterdam UMC - location VUmc
      Oct 28, 2021

      Endometriosis Trial in Rochester (F-18 FES)

      Enrolling by invitation
      • Endometriosis
      • F-18 FES
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Oct 17, 2022

      Non-invasive Dual-Pet Information in Subtype of Metastatic

      Recruiting
      • Breast Cancer
      • biopsy or surgical pathology in metastases
      • 68Ga-HER2 affibody,18F-FDG, 18F-FES
      • Shanghai, Shanghai, China
        Shanghai Cancer Center Institutional Review Board
      Apr 19, 2022